Literature DB >> 10433931

Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.

S H Bigner1, M R Matthews, B K Rasheed, R N Wiltshire, H S Friedman, A H Friedman, T T Stenzel, D M Dawes, R E McLendon, D D Bigner.   

Abstract

Oligodendroglial neoplasms are a subgroup of gliomas with distinctive morphological characteristics. In the present study we have evaluated a series of these tumors to define their molecular profiles and to determine whether there is a relationship between molecular genetic parameters and histological pattern in this tumor type. Loss of heterozygosity (LOH) for 1p and 19q was seen in 17/23 (74%) well-differentiated oligodendrogliomas, in 18/23 (83%) anaplastic oligodendrogliomas, and in 3/8 (38%) oligoastrocytomas grades II and III. LOH for 17p and/or mutations of the TP53 gene occurred in 14 of these 55 tumors. Only one of the 14 cases with 17p LOH/TP53 gene mutation also had LOH for 1p and 19q, and significant astrocytic elements were seen histologically in the majority of these 14 tumors. LOH for 9p and/or deletion of the CDKN2A gene occurred in 15 of these 55 tumors, and 11 of these cases were among the 24 (42%) anaplastic oligodendrogliomas. Comparative genomic hybridization (CGH) identified the majority of cases with 1p and 19q loss and, in addition, showed frequent loss of chromosomes 4, 14, 15, and 18. These findings demonstrate that oligodendroglial neoplasms usually have loss of 1p and 19q whereas astrocytomas of the progressive type frequently contain mutations of the TP53 gene, and that 9p loss and CDKN2A deletions are associated with progression from well-differentiated to anaplastic oligodendrogliomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10433931      PMCID: PMC1866844          DOI: 10.1016/S0002-9440(10)65134-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  21 in total

Review 1.  Treatment of oligodendroglioma: an update.

Authors:  N A Paleologos; J G Cairncross
Journal:  Neuro Oncol       Date:  1999-01       Impact factor: 12.300

2.  Deletion mapping of chromosome 19 in human gliomas.

Authors:  A von Deimling; J Nagel; B Bender; D Lenartz; J Schramm; D N Louis; O D Wiestler
Journal:  Int J Cancer       Date:  1994-06-01       Impact factor: 7.396

3.  Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors.

Authors:  A Kallioniemi; O P Kallioniemi; D Sudar; D Rutovitz; J W Gray; F Waldman; D Pinkel
Journal:  Science       Date:  1992-10-30       Impact factor: 47.728

4.  Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.

Authors:  Z A Khatib; H Matsushime; M Valentine; D N Shapiro; C J Sherr; A T Look
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

5.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

6.  Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors.

Authors:  M J Bello; J Vaquero; J M de Campos; M E Kusak; J L Sarasa; J Saez-Castresana; A Pestana; J A Rey
Journal:  Int J Cancer       Date:  1994-04-15       Impact factor: 7.396

7.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

Authors:  J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis
Journal:  J Natl Cancer Inst       Date:  1998-10-07       Impact factor: 13.506

8.  CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.

Authors:  J He; J R Allen; V P Collins; M J Allalunis-Turner; R Godbout; R S Day; C D James
Journal:  Cancer Res       Date:  1994-11-15       Impact factor: 12.701

9.  Alterations of the TP53 gene in human gliomas.

Authors:  B K Rasheed; R E McLendon; J E Herndon; H S Friedman; A H Friedman; D D Bigner; S H Bigner
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

Review 10.  Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors.

Authors:  O P Kallioniemi; A Kallioniemi; J Piper; J Isola; F M Waldman; J W Gray; D Pinkel
Journal:  Genes Chromosomes Cancer       Date:  1994-08       Impact factor: 5.006

View more
  60 in total

1.  Liver metastatic ability of human melanoma cell line is associated with losses of chromosomes 4, 9p21-pter and 10p.

Authors:  Z Adám; R Adány; A Ladányi; J Tímár; M Balázs
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Extradural cord compression due to metastatic oligodendroglioma.

Authors:  Jeff Garner; Yehya Morcos; Mohammed Bari
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

Review 3.  Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

Authors:  Adelheid Woehrer; Johannes A Hainfellner
Journal:  CNS Oncol       Date:  2015-11-06

4.  Oligodendrogliomas: a short history of clinical developments.

Authors:  Martin J van den Bent
Journal:  CNS Oncol       Date:  2015

5.  PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis.

Authors:  H Sasaki; M C Zlatescu; R A Betensky; Y Ino; J G Cairncross; D N Louis
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

6.  The importance of genomic copy number changes in the prognosis of glioblastoma multiforme.

Authors:  Ali Arslantas; Sevilhan Artan; Ulkü Oner; Hamza Müslümanoğlu; Ramazan Durmaz; Erhan Cosan; Metin Ant Atasoy; Nurettin Başaran; Eşref Tel
Journal:  Neurosurg Rev       Date:  2003-07-04       Impact factor: 3.042

Review 7.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

8.  Success at last: a molecular factor that informs treatment.

Authors:  Andrew B Lassman
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

9.  Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity.

Authors:  Brian Thiessen; John A Maguire; Kelly McNeil; David Huntsman; Montgomery A Martin; Doug Horsman
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

10.  Identification of two contiguous minimally deleted regions on chromosome 1p36.31-p36.32 in oligodendroglial tumours.

Authors:  Z Dong; Jc-S Pang; M H Ng; W S Poon; L Zhou; H-K Ng
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.